Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics

Show simple item record Fang, Zhuo Van der Merwe, Ruben Gerhard Warren, Robin M. Schubert, Wolf-Dieter Gey van Pittius, Nicolaas C. 2015-05-19T07:36:54Z 2015-05-19T07:36:54Z 2015-03
dc.description.abstract Tuberculosis threatens human health nowhere more than in developing countries with large malnourished and/or immune-compromised (e.g. HIV infected) populations. The etiological agent, Mycobacterium tuberculosis (Mtb), is highly infectious and current interventions demonstrate limited ability to control the epidemic in particular of drug resistant Mtb strains. New drugs and vaccines are thus urgently required. Structural biologists are critical to the TB research community. By identifying potential drug targets and solving their three dimensional structures they open new avenues of identifying potential inhibitors complementing the screening of novel compounds and the investigation of Mtb's molecular physiology by pharmaceutical companies and academic researchers. Much effort has gone into structurally elucidating the Mtb proteome though much remains to be done with progress primarily limited by technological constraints. We review the currently available data for Mtb H37Rv to extract the lessons they have taught us. en_ZA
dc.description.librarian hb2015 en_ZA
dc.description.uri en_ZA
dc.identifier.citation Fang, Z., Van der Merwe, RG, Warren, RM, Schubert, W-D & Gey Van Pittius, NC 2015, 'Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics', Tuberculosis, vol, 95, no. 2, pp. 131-136. en_ZA
dc.identifier.issn 1472-9792 (print)
dc.identifier.issn 1873-281X (online)
dc.identifier.other 10.1016/
dc.language.iso en en_ZA
dc.publisher Elsevier en_ZA
dc.rights © 2015 Published by Elsevier Ltd. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in Tuberculosis. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Tuberculosis, vol. 95, no. 2, pp. 131-136, 2015. doi :10.1016/ en_ZA
dc.subject Structural genomics en_ZA
dc.subject Drug target en_ZA
dc.subject Mycobacterium tuberculosis (MTB) en_ZA
dc.subject Tuberculosis (TB) en_ZA
dc.title Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics en_ZA
dc.type Postprint Article en_ZA

Files in this item

This item appears in the following Collection(s)

Show simple item record